The United Kingdom and the United States have reached a major bilateral deal that will guarantee no tariffs on UK drug shipments being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to increase funding on drugs through the public health system. This commitment secures that import taxes on these crucial products will remain at nothing for a timeframe of 36 months.
This deal comes after previous statements to significantly raise import taxes on branded pharmaceutical products, with increases floated as high as one hundred percent.
"This agreement with the United Kingdom bolsters the worldwide climate for innovative medicines and introduces long-overdue equity to U.S.–U.K. medicine commerce," an announcement noted.
Economic Significance
Medicines represent one of the UK's most significant goods shipped to the US, which is clearly the primary market for leading British pharmaceutical firms.
Trade data indicate that in the one-year period leading up to last September, the UK sold drugs totaling £11.1bn to the US. This figure represented 17.4% of all goods exports in that timeframe.
"This deal safeguards work, increases funding and facilitates the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Detailed British Pledges
The pact includes several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to increase overall NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must refund to the NHS to control costs will be capped at fifteen percent. Last year, repayments topped twenty percent.
Industry Background
This agreement comes amid a ongoing tension between the drug companies and the UK government over spending levels and NHS adoption.
The disagreement were heightened by assertions that American customers were paying several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS had to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a proportion of its resources over the past decade.
